Prognosis and mechanism of death in treated heart failure

data from the placebo arm of Val-HeFT.

Jay N. Cohn, Peter E. Carson, Christopher O'Connor, Cristina Opasich, Ileana L. Pina, Marino Scherillo, Gianfranco Sinagra, Lynne Warner-Stevenson, Felix E. Tristani, Alberto Volpi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The magnitude of benefit on mortality of combined angiotensin-converting enzyme inhibitor (ACEI) and beta-blocker (BB) therapy for heart failure cannot be reliably assessed from prospective randomized trials of individual drugs with intent-to-treat analysis. The placebo arm of the Valsartan Heart Failure Trial (Val-HeFT) included patients who remained on background therapy with ACEIs, BBs, neither, or both. The outcomes in these four subgroups should provide a better guide to mortality benefit. Overall mortality (mean follow-up, 23 months) was 31.6% in those receiving neither neurohormonal blocker, 29% and 39% lower in those on ACEIs or BBs, respectively, and 62% lower (11.9% mortality) in those receiving both drugs. In the neither neurohormonal inhibitor group, 48% of the heart failure-related deaths were adjudicated as sudden, whereas in the group receiving ACEIs and BBs, 79% of the deaths were sudden, and pump failure mortality was only 1% per year. The combination of ACEIs and BBs exerts a greater mortality reduction than suggested from clinical trials and reduces pump failure mortality to 1% per year.

Original languageEnglish (US)
Pages (from-to)127-131
Number of pages5
JournalCongestive heart failure (Greenwich, Conn.)
Volume12
Issue number3
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Valsartan
Heart Failure
Placebos
Mortality
Sudden Death
Angiotensin-Converting Enzyme Inhibitors
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognosis and mechanism of death in treated heart failure : data from the placebo arm of Val-HeFT. / Cohn, Jay N.; Carson, Peter E.; O'Connor, Christopher; Opasich, Cristina; Pina, Ileana L.; Scherillo, Marino; Sinagra, Gianfranco; Warner-Stevenson, Lynne; Tristani, Felix E.; Volpi, Alberto.

In: Congestive heart failure (Greenwich, Conn.), Vol. 12, No. 3, 05.2006, p. 127-131.

Research output: Contribution to journalArticle

Cohn, JN, Carson, PE, O'Connor, C, Opasich, C, Pina, IL, Scherillo, M, Sinagra, G, Warner-Stevenson, L, Tristani, FE & Volpi, A 2006, 'Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.', Congestive heart failure (Greenwich, Conn.), vol. 12, no. 3, pp. 127-131. https://doi.org/10.1111/j.1527-5299.2006.05441.x
Cohn, Jay N. ; Carson, Peter E. ; O'Connor, Christopher ; Opasich, Cristina ; Pina, Ileana L. ; Scherillo, Marino ; Sinagra, Gianfranco ; Warner-Stevenson, Lynne ; Tristani, Felix E. ; Volpi, Alberto. / Prognosis and mechanism of death in treated heart failure : data from the placebo arm of Val-HeFT. In: Congestive heart failure (Greenwich, Conn.). 2006 ; Vol. 12, No. 3. pp. 127-131.
@article{7689ed09cefc465688ae55d7766d4da8,
title = "Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.",
abstract = "The magnitude of benefit on mortality of combined angiotensin-converting enzyme inhibitor (ACEI) and beta-blocker (BB) therapy for heart failure cannot be reliably assessed from prospective randomized trials of individual drugs with intent-to-treat analysis. The placebo arm of the Valsartan Heart Failure Trial (Val-HeFT) included patients who remained on background therapy with ACEIs, BBs, neither, or both. The outcomes in these four subgroups should provide a better guide to mortality benefit. Overall mortality (mean follow-up, 23 months) was 31.6{\%} in those receiving neither neurohormonal blocker, 29{\%} and 39{\%} lower in those on ACEIs or BBs, respectively, and 62{\%} lower (11.9{\%} mortality) in those receiving both drugs. In the neither neurohormonal inhibitor group, 48{\%} of the heart failure-related deaths were adjudicated as sudden, whereas in the group receiving ACEIs and BBs, 79{\%} of the deaths were sudden, and pump failure mortality was only 1{\%} per year. The combination of ACEIs and BBs exerts a greater mortality reduction than suggested from clinical trials and reduces pump failure mortality to 1{\%} per year.",
author = "Cohn, {Jay N.} and Carson, {Peter E.} and Christopher O'Connor and Cristina Opasich and Pina, {Ileana L.} and Marino Scherillo and Gianfranco Sinagra and Lynne Warner-Stevenson and Tristani, {Felix E.} and Alberto Volpi",
year = "2006",
month = "5",
doi = "10.1111/j.1527-5299.2006.05441.x",
language = "English (US)",
volume = "12",
pages = "127--131",
journal = "Congestive Heart Failure",
issn = "1527-5299",
publisher = "Le Jacq Communications, Inc.",
number = "3",

}

TY - JOUR

T1 - Prognosis and mechanism of death in treated heart failure

T2 - data from the placebo arm of Val-HeFT.

AU - Cohn, Jay N.

AU - Carson, Peter E.

AU - O'Connor, Christopher

AU - Opasich, Cristina

AU - Pina, Ileana L.

AU - Scherillo, Marino

AU - Sinagra, Gianfranco

AU - Warner-Stevenson, Lynne

AU - Tristani, Felix E.

AU - Volpi, Alberto

PY - 2006/5

Y1 - 2006/5

N2 - The magnitude of benefit on mortality of combined angiotensin-converting enzyme inhibitor (ACEI) and beta-blocker (BB) therapy for heart failure cannot be reliably assessed from prospective randomized trials of individual drugs with intent-to-treat analysis. The placebo arm of the Valsartan Heart Failure Trial (Val-HeFT) included patients who remained on background therapy with ACEIs, BBs, neither, or both. The outcomes in these four subgroups should provide a better guide to mortality benefit. Overall mortality (mean follow-up, 23 months) was 31.6% in those receiving neither neurohormonal blocker, 29% and 39% lower in those on ACEIs or BBs, respectively, and 62% lower (11.9% mortality) in those receiving both drugs. In the neither neurohormonal inhibitor group, 48% of the heart failure-related deaths were adjudicated as sudden, whereas in the group receiving ACEIs and BBs, 79% of the deaths were sudden, and pump failure mortality was only 1% per year. The combination of ACEIs and BBs exerts a greater mortality reduction than suggested from clinical trials and reduces pump failure mortality to 1% per year.

AB - The magnitude of benefit on mortality of combined angiotensin-converting enzyme inhibitor (ACEI) and beta-blocker (BB) therapy for heart failure cannot be reliably assessed from prospective randomized trials of individual drugs with intent-to-treat analysis. The placebo arm of the Valsartan Heart Failure Trial (Val-HeFT) included patients who remained on background therapy with ACEIs, BBs, neither, or both. The outcomes in these four subgroups should provide a better guide to mortality benefit. Overall mortality (mean follow-up, 23 months) was 31.6% in those receiving neither neurohormonal blocker, 29% and 39% lower in those on ACEIs or BBs, respectively, and 62% lower (11.9% mortality) in those receiving both drugs. In the neither neurohormonal inhibitor group, 48% of the heart failure-related deaths were adjudicated as sudden, whereas in the group receiving ACEIs and BBs, 79% of the deaths were sudden, and pump failure mortality was only 1% per year. The combination of ACEIs and BBs exerts a greater mortality reduction than suggested from clinical trials and reduces pump failure mortality to 1% per year.

UR - http://www.scopus.com/inward/record.url?scp=33746058333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746058333&partnerID=8YFLogxK

U2 - 10.1111/j.1527-5299.2006.05441.x

DO - 10.1111/j.1527-5299.2006.05441.x

M3 - Article

VL - 12

SP - 127

EP - 131

JO - Congestive Heart Failure

JF - Congestive Heart Failure

SN - 1527-5299

IS - 3

ER -